Targets › C3
9 programs from 6 companies in 14 trials: 5 Phase 2, 4 Phase 3, 4 Phase 1, 1 Phase 4; Genitourinary, Ophthalmology, Other; next expected readout Dec 2026.
Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system..; FUNCTION: [Complement C3b]: Non-enzymatic component of C5 convertase. Generated following cleavage by C3 convertase, it covalently attaches to the surface of…. (UniProt, P01024)
Open in Phaseline: the race on C3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Pegcetacoplan Complement C3 inhibitor | C3 | Phase 4 | C3 Glomerulopathy (C3G) | Dec 2031 |
| Annexon | Tanruprubart (ANX005) C3 complement inhibitor | C3 | Phase 3 | Guillain-Barre Syndrome | May 2027 |
| Apellis Pharmaceuticals | Pegcetacoplan Complement C3 inhibitor | C3 | Phase 3 | C3G; Paroxysmal Nocturnal Hemoglobinuria (PNH); Fallopian Tube Carcinosarcoma; Metastatic Pancreatic Ductal Adenocarcinoma | Jul 2027 |
| Annexon | Vonaprument (ANX007) Complement 3 (C3) inhibitor | C3 | Phase 3 | Geographic Atrophy | Jul 2027 |
| Kodiak Sciences | Tarcocimab tedromer Monoclonal antibody against complement factor C3 | C3 | Phase 3 | Wet Age-related Macular Degeneration | Aug 2027 |
| Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) | RG002C0106 siRNA targeting complement C3 to silence the gene and inhibit C3 protein expression | C3 | Phase 2 | IgA Nephropathy (IgAN); Safety Issues; Renal Impairments | Dec 2026 |
| Apellis Pharmaceuticals | APL-3007 Complement C3 inhibitor | C3 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Jun 2027 |
| Apellis Pharmaceuticals | APL2 Complement C3 inhibitor | C3 | Phase 2 | FSGS | Oct 2029 |
| Shenyang Sunshine Pharmaceutical | SSS55 injection complement C3b inhibitor | C3 | Phase 1 | Safety Issues | Dec 2026 |
Safety Issues (2) FSGS (1) C3G (1) Paroxysmal Nocturnal Hemoglobinuria (PNH) (1) Fallopian Tube Carcinosarcoma (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Wet Age-related Macular Degeneration (1) IgA Nephropathy (IgAN) (1) Renal Impairments (1) Geographic Atrophy (1) Guillain-Barre Syndrome (1) Geographic Atrophy Secondary to Age-related Macular Degeneration (1)
small molecule (7), mixed (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.